The Signaling and Pharmacology of the Dopamine D1 Receptor

Frontiers in Cellular Neuroscience

Cellular Neuroscience

Jace Jones-Tabah¹  Emma G. Paulus¹  Hanan Mohammad¹  Terence E. Hébert²  Paul B. S. Clarke² 

[1] Department of Pharmacology and Therapeutics, McGill University, Montreal, QC, Canada;null;

关键词: G protein-coupled receptors;    dopamine D1 receptor;    intracellular signaling;    drug development;    biased agonism;    Parkinson's Disease;    cognitive impairment (CI);   

DOI  :  10.3389/fncel.2021.806618

 received in 2021-11-01, accepted in 2021-12-23,  发布年份 2022

来源: Frontiers

【 摘 要 】

The dopamine D1 receptor (D1R) is a Gαs/olf-coupled GPCR that is expressed in the midbrain and forebrain, regulating motor behavior, reward, motivational states, and cognitive processes. Although the D1R was initially identified as a promising drug target almost 40 years ago, the development of clinically useful ligands has until recently been hampered by a lack of suitable candidate molecules. The emergence of new non-catechol D1R agonists, biased agonists, and allosteric modulators has renewed clinical interest in drugs targeting this receptor, specifically for the treatment of motor impairment in Parkinson's Disease, and cognitive impairment in neuropsychiatric disorders. To develop better therapeutics, advances in ligand chemistry must be matched by an expanded understanding of D1R signaling across cell populations in the brain, and in disease states. Depending on the brain region, the D1R couples primarily to either Gαs or Gαolf through which it activates a cAMP/PKA-dependent signaling cascade that can regulate neuronal excitability, stimulate gene expression, and facilitate synaptic plasticity. However, like many GPCRs, the D1R can signal through multiple downstream pathways, and specific signaling signatures may differ between cell types or be altered in disease. To guide development of improved D1R ligands, it is important to understand how signaling unfolds in specific target cells, and how this signaling affects circuit function and behavior. In this review, we provide a summary of D1R-directed signaling in various neuronal populations and describe how specific pathways have been linked to physiological and behavioral outcomes. In addition, we address the current state of D1R drug development, including the pharmacology of newly developed non-catecholamine ligands, and discuss the potential utility of D1R-agonists in Parkinson's Disease and cognitive impairment.

【 授权许可】

Unknown   
Copyright © 2022 Jones-Tabah, Mohammad, Paulus, Clarke and Hébert.